EKF specialises in diagnostics and biotechnology patient-centric solutions
EKF is a leading global diagnostics and biotechnology company specialising in the development, production, and distribution of innovative medical technologies and patient-centric solutions.
Welcome to our investor relations pages, where you can find official investor-focused news, reports, and presentations.
At EKF, our mission is to improve global healthcare by providing innovative solutions that empower medical professionals and enhance patient outcomes.
We are dedicated to developing and delivering high-quality, reliable, cost-effective tools and technologies that enable the early detection, accurate diagnosis, therapeutic development, and effective monitoring of conditions and diseases.
Through our commitment to excellence, collaboration, and customer satisfaction, we aim to make a positive impact on the lives of individuals and the healthcare industry by advancing the fields of point-of-care and life sciences.
EKF Diagnostics Holdings plc is an AIM-listed company based in Penarth, near Cardiff in the UK. We have manufacturing sites in the US and Germany and partner with a distribution network to sell our products in over 120 countries.
EKF Diagnostics Holdings plc is subject to the City Code on Takeover and Mergers, as published by the Takeover Panel and updated from time to time.
This section provides access to EKF Diagnostics Holdings PLC's Regulatory News Service (RNS) announcements, including investor updates, product news, and significant company developments, ensuring stakeholders are informed of the latest official communications.
Find out moreThis section provides EKF Diagnostics Holdings PLC’s live share price information, offering real-time updates and historical performance data, as well as the latest trades, helping investors and others stay informed about market trends and the company’s stock performance.
Find out moreThis section provides critical corporate information required for AIM Rule 26 compliance, including details about EKF Diagnostics Holdings PLC’s business, directors, governance, shareholder structure, and significant shareholders, ensuring transparency for investors.
Find out moreThis section outlines EKF Diagnostics Holdings PLC's corporate governance framework, including board responsibilities, committee structures, compliance with governance codes, internal controls, and shareholder relations, ensuring accountability and transparency for investors.
Find out moreThis section offers profiles of EKF Diagnostics Holdings PLC's key directors and advisors, detailing their professional backgrounds and roles within the company. It also includes information on the company's nominated advisors, auditors, and other essential advisors.
Find out moreThis section provides essential documents and reports for investors, including financial statements, investor presentations, and shareholder communications, offering comprehensive insights into EKF Diagnostics Holdings PLC's corporate and operational activities.
Find out moreEKF develops and manufactures point-of-care medical devices and tests (in-vitro diagnostics (IVD)) that can be used at or near the patient’s location. Designed to provide quick and accurate results, these tests enable healthcare professionals to make rapid decisions.
Find out moreEKF develops and supplies reagents, enzymes, and other components used in the research, biotechnology, and pharmaceutical industries. Dedicated to supporting clinicians, scientists and researchers with high-quality materials for use in industrial and life sciences applications.
Find out moreEKF develops and provides a range of devices, tests, and media for high-throughput, accurate analysis in central laboratory settings. Our advanced technology ensures reliable results that support healthcare professionals with the precise diagnostics required on a large scale.
Find out moreWalbrook PR
Tel: +44 (0)20 7933 8780
Email: ekf@walbrookpr.com
£52.6m
Revenue
£24.4m
Gross profit before exceptionals
£10.4m
Adjusted EBITDA
If you are approached by someone offering to buy your EKF shares at a considerable premium to the market price, please do not engage with them, they are operating an advance fee fraud, where you will be asked to make a payment up front in order to make the transaction happen. If you *do* make such a payment, they will just come back for more.